Investor profile
M Ventures
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany, with a dual remit of strategic and financial returns. With a €600m fund allocation, it invests globally in Biotechnology and Technology — spanning Healthcare drug development, Life Science tools, Electronics, and Frontier Technology & Sustainability — backing visionary companies that find new ways to treat challenging diseases, empower scientists with cutting-edge R&D tools, and develop solutions that change how information is accessed, stored, processed, and displayed. M Ventures takes an active, hands-on role in its portfolio companies, teaming up with entrepreneurs and co-investors to translate scientific innovation into commercial success. Where necessary, team members take on operational roles such as interim CEO, Chairperson, CBO, or CFO. The fund operates from its Netherlands headquarters with offices in Germany, Israel, and the USA, investing from Seed through to later-stage rounds and supporting companies all the way to IPO or M&A exit.
Notable quotes
“These appointments reflect our commitment to fostering internal talent and to build on our strong position in the venturing and innovation ecosystem. These leadership changes will ensure a seamless transition and allow M Ventures to continue its impressive track record of investing in innovative startups that align with Merck KGaA, Darmstadt, Germany's mission.”
“Together with the current blue-chip investors like Sofinnova Partners, who led the series A round, we welcome the new strong investor group to continue supporting the company in this significant phase of development.”
“The rapid advance of AI opens up new opportunities for the company in areas like semiconductors and photonics, and we aim to expand the scope of M Ventures' investments, continuing its early-stage activity while doing more at late stage.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| STORM Therapeutics | Series C | — | 2026-04-16 |
| ImmuneBridge | Seed | $8m | 2026-03-24 |
| FoRx Therapeutics | Series A | — | 2025-12-18 |
| Artios | Series B+ | — | 2025-11-17 |
| Ferroelectric Memory GmbH | Later Stage VC | — | 2025-11-13 |
| Actithera | Series A | $76m | 2024-01-01 |
| Nouscom | Series B | $75m | 2022-01-01 |
| MemryX | Series A | — | 2023-01-01 |
| Synaffix BV | Series A | — | 2020-01-01 |
| Progyny | Series C | — | 2018-01-01 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Sofinnova Partners | 6 |
| Novo Holdings | 5 |
| Johnson & Johnson Innovation – JJDC | 4 |
| SR One | 3 |
| Atlas Venture | 3 |
| EQT Life Sciences | 3 |
Fit check
Is M Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit